CBI-MI

CBI-MI is a synthetic duocarmycin analogue consisting of a 1-(chloromethyl)-5-hydroxy-1,2-dihydro-3H-benzo[e]indole (CBI) alkylating subunit coupled to a 5-methoxyindole-2-carbonyl (MI) DNA-binding subunit. As a member of the duocarmycin class of antitumor antibiotics, CBI-MI functions as an ultrapotent DNA alkylating agent that binds to the minor groove of duplex DNA and induces sequence-selective alkylation, leading to DNA damage and cell death. CBI-MI is widely utilized as a reference control and a cytotoxic payload in the design and preclinical evaluation of antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs), such as those targeting CD13 (aminopeptidase N) developed by the Institute of Cancer Therapeutics at the University of Bradford.

Other names

seco-CBI-MI